Nick Hodge’s EARLY ADVANTAGE.FDA-mandated machineWhat is the little company that reportedly holds the patents on the FDA-mandated machine that that detects deadly pathogens. To find out, you have to buy Nick Hodge’s EARLY ADVANTAGE.
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Wish I knew! Dnatrax and safe trace seem to be companies formed for this but nipt listed yet.
Hello, all I found was a private company called MOgene LC that received a recent license from Lawrence Livermore National Laboratory (LLNL) as the supplier of DNA Micro Arrays. This will find pathogens, but it will have to be done at the laboratory there and will take up to 24 hours.
Need the Thinkolator….
Lexagene Holdings Inc??
Lexogene?
Well done PAUL! I’m convinced it’s lexagene, LXG.V. Here’s some of the blurb:
But what really convinced me is Nick Hodges latest spiel shows 4 photos of the different phases of this detector and the SAME photos are shown on their website. I’m going to have a punt on this one, as it can analyse a pathogen in 1 hour as opposed to 7 days normally.
…..
Developed at one of the world’s most sophisticated science laboratories
If you know your way around the tech sector, you’re probably already familiar with the Lawrence Livermore National Laboratory. For more than 60 years, this federally funded laboratory has produced the most cutting-edge defense, security, science and energy technologies around. Every once in a while, a Lawrence Livermore funded prototype gets spun out of its laboratories and licensed into the private sector. It was under these circumstances that LexaGene’s founder and CEO, Dr. Jack Regan, developed and patented the LX6 prototype.
Dr. Jack Regan was no stranger to Lawrence Livermore, having completed his doctoral training there, where he developed instruments to detect respiratory pathogens and bio-threat agents.
Dr. Regan later played an instrumental role in building the value in QuantaLife that led to its $162 Million buyout by microbiology giant, Bio-Rad. Point being, this is a man who understands how to bring a concept to commercialization. And he’s using those skills to bring LXXGF/LXG first to market with a rapid pathogen detection system.
And that could happen much sooner than you’d expect…
Sounds right – fits the description, including the executive who came from Auryn